Wedbush Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $16
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsInitiationPrice Target
Wedbush analyst Yun Zhong initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Outperform rating and announces Price Target of $16.
Wedbush analyst Yun Zhong initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Outperform rating and announces Price Target of $16.